Log in | Register

E-mail
Company Name

AEterna Zentaris' Anti-Cancer Compound, Perifosine, Receives FDAFast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma

Loading...
AEterna Zentaris Inc., a global biopharmaceutical companyfocused on endocrine therapy and oncology, today announced that the FDA has granted Fast Track designation for thecompany's PI3K/Akt pathway inhibitor compound, perifosine (KRX-0401), for thetreatment of relapsed/refractory multiple myeloma. Keryx Biopharmaceuticals,Inc., is AEterna Zentaris' partner and licensee forperifosine in the United States, Canada and Mexico. Perifosine is alsoout-licensed to Handok in South Korea while AEterna Zentaris retains rightsfor the rest of the world.

The Fast Track program of the FDA is designed to facilitate thedevelopment and expedite the review of new drugs that are intended to treatserious or life-threatening conditions and that demonstrate the potential toaddress unmet medical needs. Fast Track designated drugs ordinarily qualifyfor priority review, thereby expediting the FDA review process.

"We are very pleased with the FDA's Fast Track designation and we lookforward to the emergence of the data from the forthcoming Phase 3 clinicaltrial in multiple myeloma to be conducted by our partner Keryx, which we hopewill establish perifosine as a novel treatment of this serious condition",stated Juergen Engel, Ph.D., President and CEO at AEterna Zentaris. "Wefurther believe that this North American clinical development program willalso be very useful to support the development and registration of perifosinefor the benefit of patients in the rest of the world."

A Phase 3 trial investigating perifosine in combination with bortezomib(VELCADE(R)) and dexamethasone for the treatment of patients withrelapsed/refractory multiple myeloma is expected to commence by year-end undera Special Protocol Assessment (SPA) with the FDA. In addition, in September,perifosine had received Orphan-Drug designation in the United States for thetreatment of multiple myeloma.
Join the Discussion
Rate Article:  Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Blogs

The Importance of Fundamentals

The Importance of Fundamentals

Aug 31 | Girish Malhotra, PE, President, EPCOT International

Globally, Johnson & Johnson is known for its integrity and product quality. A few years ago they handled the Tylenol situation extremely well and were commended for it. It is astounding that the year 2010 has become a nightmare for them.  

The Quality Control Unit: Invertebrates Need Not Apply

The Quality Control Unit: Invertebrates Need Not Apply

Aug 30 | The QA Pharm

The Quality Control Unit (QCU) is the only pharmaceutical function that has a job description codified in the CGMP regulations. Don’t you find this remarkable? In fact, an entire section is devoted to describing the responsibility of the QCU and how it is to operate within the organization—namely independently.        

Multimedia

Timothy Cote - Office of Orphan Products Development

Aug 13 | Root

From approving medicines to treating snake bites to Cystic Fibrosis - Dr. Tim Cote describes a special office at the FDA, designed to address needs of people with rare diseases. Timothy Cote, M.D. - Director, Office of Orphan Products Development

Charles River Labs On WuXi PharmaTech Acquisition

Charles River Labs On WuXi PharmaTech Acquisition

May 25 | Video

Charles Rivers Laboratories International Chief Officer talks about the recent WuXi PharmaTech acquisition

Biogen Idec - 2010 Facility of the Year Award Winner - Operational Excellence

Biogen Idec - 2010 Facility of the Year Award Winner - Operational Excellence

Apr 27 | Video

Peter Flinn, Biogen Idec's Senior Director, Global Project Engineering talks to Pharmaceutical Processing's Editor-In-Chief Mike Auerbach about the company's Large-Scale Manufacturing Technology Map Project in Research Triangle Park, North Carolina. The project won the 2010 Operational...

MannKind Corporation - 2010 Facility of the Year Award Winner - Equipment & Process Innovation

MannKind Corporation - 2010 Facility of the Year Award Winner - Equipment & Process Innovation

Apr 28 | Video

Juergen Martens, Ph,D. MannKind Corporation's Corporate Vice President and Chief Technical Officer talks to Pharmaceutical Processing's Editor-In-Chief Mike Auerbach durng INTERPHEX2010 about the company's Technosphere Insulin Manufacturing Facility located in Danbury, Connecticut. The...